Zealand Q3 ’18 Earnings; Xeris Initiates New Ph3 Study vs. GlucaGen

Zealand hosted its Q3 ’18 earnings call and provided updates to its dasiglucagon development program. Additionally, a new Ph3 Xeris glucagon study vs. Novo’s GlucaGen has been observed. Of note, Zealand narrowed its filing timeline for dasiglucagon hypoglycemia from H2 ’19 to Q4 ’19. Below, FENIX provides thoughts on the dasiglucagon hypoglycemia rescue program, Zealand’s ongoing partnership discussions for dasiglucagon commercialization, and Xeris’s new Ph3 study.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.